ETC
ZYNE

Exchange Traded Concepts’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Exchange Traded Concepts’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,733
Closed -$9.93K – 1311
2022
Q4 		$9.93K Buy
18,733
+11,562
+161% +$7.33K ﹤0.01% 1000
2022
Q3 		$5K Buy
7,171
+1,018
+17% +$1.16K ﹤0.01% 1079
2022
Q2 		$7K Buy
6,153
+4,825
+363% +$6.14K ﹤0.01% 1120
2022
Q1 		$3K Buy
+1,328
New +$3.16K ﹤0.01% 1181

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exchange Traded Concepts's ZYNE Position: Q1 2023 in Review

Exchange Traded Concepts sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 18,733 shares — an estimated $9.93K sold.

Exchange Traded Concepts first reported a position in ZYNE in Q1 2022 and held it in 4 quarters. The position peaked at $9.93K in Q4 2022. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Exchange Traded Concepts reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Exchange Traded Concepts sold 18,733 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $9.93K.
  • Exchange Traded Concepts first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2022 and held it in 4 quarters.
  • Exchange Traded Concepts's Zynerba Pharmaceuticals, Inc position peaked at $9.93K in Q4 2022.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Exchange Traded Concepts's 13F filing for Q1 2023, filed 12 Apr 2023.